Safety and Efficacy of Drug-Eluting Beads Trans-Arterial Chemoembolization for Hepatocellular Carcinoma in Taiwan (SERENADE-T)

Yi-Sheng Liu; Pi-Yi Chang; Po-Chin Liang; Ming-Ching Ou; Jen-I Hwang; Chien-Hung Chen

doi:10.2147/JHC.S374555

Safety and Efficacy of Drug-Eluting Beads Trans-Arterial Chemoembolization for Hepatocellular Carcinoma in Taiwan (SERENADE-T)

J Hepatocell Carcinoma. 2022 Aug 15:9:811-821. doi: 10.2147/JHC.S374555. eCollection 2022.

Authors

Yi-Sheng Liu¹, Pi-Yi Chang², Po-Chin Liang³, Ming-Ching Ou⁴, Jen-I Hwang^{5

6}, Chien-Hung Chen^{7

8}

Affiliations

¹ Department of Medical Imaging, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
² Department of Radiology, Taichung Veterans General Hospital, Taichung City, Taiwan.
³ Department of Radiology, National Taiwan University Hospital, Taipei City, Taiwan.
⁴ Department of Diagnostic Radiology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
⁵ Department of Medical Imaging, Tungs' Taichung MetroHarbor Hospital, Taichung City, Taiwan.
⁶ Department of Radiology, School of Medicine, National Defense Medical Center, Taipei City, Taiwan.
⁷ Department of Internal Medicine, National Taiwan University Hospital Yunlin Branch, Douliu City, Yunlin County, Taiwan.
⁸ Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei City, Taiwan.

Abstract

Purpose: The aim of this retrospective study was to evaluate the safety and efficacy of patients with hepatocellular carcinoma treated with drug-eluting bead with doxorubicin transarterial chemoembolization (DEBDOX-TACE) in Taiwan.

Patients and methods: We retrospectively investigated 630 hepatocellular carcinoma patients who underwent DEBDOX-TACE in multiple institutions from 2011 to 2016 in Taiwan. Tumor response was assessed per modified response evaluation criteria in solid tumors, overall survival, and safety.

Results: This study included 630 patients who underwent DEBDOX-TACE, participants' mean age was 66 years, 68.1% males and 15.6% females. The mean doxorubicin dose administered via DEBDOX-TACE was 56 mg. Complete and partial response rates were 14.6% and 49.2%, respectively, with a disease control rate of 84.6%. The median overall survival was 29.2 months. The most common post-embolization symptom was abdominal pain (22.4%). No hepatic encephalopathy and no procedure-related death were found.

Conclusion: Real-world data from Taiwan demonstrated that DEBDOX-TACE for hepatocellular carcinoma can achieve high tumor response rate with low adverse events.

Keywords: DEBDOX; chemoembolization; doxorubicin; liver cancer.